Ryan McDonald | Authors


KEYNOTE-799 Results Reveal Durable Responses in Previously Untreated Stage III NSCLC

June 09, 2022

In patients with previously untreated, locally advanced stage III non–small cell lung cancer, continued benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab was observed after more than 2 years of follow-up.